Navigation Links
Cohera Medical Raises Over $25 Million in Series C Round
Date:12/19/2011

PITTSBURGH, Dec. 19, 2011 /PRNewswire/ -- Cohera Medical, a leading innovator and developer of absorbable surgical adhesives and sealants, announced today that it has secured over $25 million Series C financing through private investors.  A total of $16.5 million was raised through existing investors and over $9 million was raised through new investors, which significantly bolstered the round.

The company will use the funds to expand adoption in Germany and additional European markets for its lead product, TissuGlu® Surgical Adhesive.  The funds will also be used to support the clinical trials for TissuGlu in the United States.  TissuGlu is an internal surgical adhesive for large flap surgeries, such as abdominoplasty (tummy tuck), that helps reduce fluid accumulation and the need for postsurgical drains. 

"In its first two months, TissuGlu has been used successfully in over 160 plastic surgery procedures in Germany by leading plastic and reconstructive surgeons," said John C. Kern, Founder and General Partner of Kern Whelan Capital, LLC, and Manager of Kern Medical III. "We believe that TissuGlu has the potential to fundamentally transform the patient recovery process worldwide, across many types of surgical procedures, while saving surgeons significant time and money through the reduction of post-surgical complications."

"In just five years, we have taken TissuGlu from a benchtop experiment to a commercially viable product – a significant achievement for our company," said Patrick Daly, President and CEO of Cohera Medical.  "We have reached several major milestones this year, and our ability to attract both new and existing investors is a reflection of their confidence that we can generate long-term and sustainable growth."

Cohera Medical recently received CE Marking approval for TissuGlu and began selling product to hospitals and surgeons in Germany in September 2011.  The company plans to expand the commercial availability of TissuGlu to additional European markets in early 2012.  Cohera Medical is also actively pursuing U.S. FDA approval.

Currently, most patients who undergo abdominoplasty procedures and other flap procedures require the insertion of drains to remove fluids that accumulate under the skin at the surgical site. In some cases, drainage is inadequate and the excess fluid accumulation (seroma) often requires additional procedures for removal. TissuGlu adheres the tissue flap to the underlying tissue (which is created during the procedure) to help reduce fluid that can accumulate in the space and ultimately reduce the time to drain removal. With the use of TissuGlu, patients may have drains removed faster, which may lead to a more comfortable recovery and a quicker return to normal activity.

According to the American Society of Plastic Surgeons, the global market for cosmetic surgery and treatments now exceeds $30 billion, with a sustainable compound annual growth rate in the range of 25%. In Europe, the market for cosmetic surgery is about $2.2 billion with a compound annual growth rate of 19% (Frost & Sullivan), and total sales of wound closure devices are expected to reach approximately $740 million in 2012 (Medtech Insight).

About Cohera Medical

Cohera Medical, Inc.® is a leading innovator and developer of absorbable surgical adhesives and sealants. The Company's first product, TissuGlu® Surgical Adhesive, is an internal surgical adhesive for large flap surgeries, such as abdominoplasty (tummy tuck), that eliminates or reduces fluid accumulation and the need for post surgical drains.  TissuGlu's chemical composition is resorbable, non-toxic, forms a strong bond between tissue layers and allows for natural healing, which ultimately may enable faster recovery. TissuGlu has received CE Marking approval to be sold in the European Union (EU).  Cohera Medical is also developing a unique and proprietary bowel sealant, and a strong adhesive for mesh fixation. Outside of the EU, TissuGlu and the other Cohera products are currently indicated for investigational use only and have not yet been approved for medical use by the Food and Drug Administration (FDA) in the U.S. or in any other market.  For more information, visit www.coheramed.com.

Certain statements made throughout this press release that are not historical facts contain forward-looking statements regarding the Company's future plans, objectives and expected performance. Any such forward-looking statements are based on assumptions that the Company believes are reasonable, but are subject to a wide range of risks and uncertainties and, therefore, there can be no assurance that actual results may not differ materially from those expressed or implied by such forward-looking statements.


'/>"/>
SOURCE Cohera Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cohera Medical Commercializes TissuGlu® Surgical Adhesive in Germany
2. Cohera Medical and CEO Receive Pittsburgh Tech 50 Awards
3. Cohera Medical Receives CE Mark Approval for TissuGlu® Surgical Adhesive
4. Frost & Sullivan Recognizes Cohera Medical, Inc.® for Developing TissuGlu®, Its Pioneering Surgical Adhesive That Is Strong, Easy-To-Use, Biocompatible and Resorbable
5. First Patient Treated in Clinical Study of Cohera Medicals TissuGlu(R) Surgical Adhesive
6. Medical Alarm Concepts™ Chosen as a Strategic Alliance Partner with Costco Warehouse Clubs
7. Medical Centers Worldwide Adopt Both Accurays CyberKnife and TomoTherapy Systems
8. Sanomedics Signs Letter of Intent to Acquire East Coast Based Durable Medical Equipment Business
9. Gerresheimer Extends Production of Medical Plastic Systems in Bavaria
10. Veran Medical Technologies Launches New SPiN Drive™ Application for Bi-Planar Virtual Fluoroscopy View
11. Saladax Biomedical, Inc. Expands Distribution of My5-FU in Europe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... April 29, 2016 ReportsnReports.com ... 2016" market research report that provides an overview ... analysis at various stages, therapeutics assessment by drug ... (RoA) and molecule type, along with latest updates, ... reviews key players involved in the therapeutic development ...
(Date:4/29/2016)... April 29, 2016 Automation is ... laboratory due to the growing demands for productivity in ... contemporary automated systems are already adept of a wide ... tedious and manual labor. Instrumentation continues to evolve, and ... conceivable just a few years ago. Originally used mostly ...
(Date:4/28/2016)... BURLINGAME, Calif. , April 28, 2016 /PRNewswire/ ... first-ever widely accessible breast and ovarian cancer risk ... cancer panel analyzing 30 genes that highly impact ... and women. Available today, the Color Test analyzes ... pancreatic, prostate, stomach, and uterine cancers. The Color ...
Breaking Medicine Technology:
(Date:5/3/2016)... NY (PRWEB) , ... May 04, 2016 , ... ... a 2016-2017 inductee into its VIP Woman of the Year Circle. She is recognized ... organization exclusively for professional women, boasting more than 850,000 members and over 200 operating ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... 2016 Champion Award to Charles D. Pulido, R.Ph., Co-Founder of NCPDP and member ... Ph.D., Pharmacy Advisor and Health IT Specialist, Office of the National Coordinator for ...
(Date:5/3/2016)... ... 2016 , ... California health startup Pegara announced today the ... assess their risk of developing Alzheimer’s disease. Using a questionnaire based on years ... Score™” that summarizes how their lifestyle choices may affect their chances of developing ...
(Date:5/3/2016)... CA (PRWEB) , ... May 03, 2016 , ... ... is a process that selects DNA or RNA from a random library of ... potentially be used as drugs or diagnostic agents. SELEX selection is commonly performed ...
(Date:5/3/2016)... Fla. (PRWEB) , ... May 03, 2016 , ... Elizabeth ... her pet parrots to join her with one on her shoulder and one on ... through a parking lot because of years of mitral valve prolapse. , The valves ...
Breaking Medicine News(10 mins):